Preservation of Alloreactive and Antiviral Immunity After Switch to Belatacept-Based Regimen After Kidney Transplantation.

被引：0
|
作者：
Schaenman, J. [1 ]
Korin, Y. [2 ]
Sidwell, T. [2 ]
Groysberg, V. [2 ]
Gadzhyan, J. [1 ]
Lum, E. [1 ]
Reddy, U. [1 ]
Huang, E. [1 ]
Pham, T. [1 ]
Danovitch, G. [1 ]
Reed, E. [2 ]
Bunnapradist, S. [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2016年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
D141
引用
收藏
页码：744 / 744
页数：1
相关论文
共 50 条
  • [31] Belatacept after kidney transplantation in adolescents: a retrospective study
    Lerch, Christian
    Kanzelmeyer, Nele K.
    Ahlenstiel-Grunow, Thurid
    Froede, Kerstin
    Kreuzer, Martin
    Drube, Jens
    Verboom, Murielle
    Pape, Lars
    TRANSPLANT INTERNATIONAL, 2017, 30 (05) : 494 - 501
  • [32] LONG-TERM OUTCOMES AFTER CONVERSION TO A BELATACEPT-BASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT: A MATCHED COHORT STUDY
    Divard, Gillian
    Debiais-Deschamps, Charlotte
    Legendre, Christophe
    Lefaucheur, Carmen
    Aubert, Olivier
    Loupy, Alexandre
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I746 - I747
  • [33] Progression of apoptosis after liver preservation and transplantation.
    Currin, RT
    Peng, XX
    Arai, M
    Thurman, RG
    Lemasters, JJ
    HEPATOLOGY, 1997, 26 (04) : 1469 - 1469
  • [34] Fracture incidence after kidney transplantation.
    deSevaux, R
    Wetzels, J
    Hoitsma, A
    KIDNEY INTERNATIONAL, 1997, 52 (02) : 576 - 576
  • [35] Patient-Reported Outcomes in a Prospective Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression Regimens in Kidney Transplantation.
    Rohan, J. M.
    Leone, J. P.
    Woodle, E. S.
    Kaufman, D.
    Shields, A. R.
    Wiseman, A.
    Matas, A. J.
    West-Thielke, P.
    King, E.
    Alloway, R. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 418 - 419
  • [36] Belatacept-based, ATG-Fresenius-induction regimen for kidney transplant recipients: A proof-of-concept study
    Cicora, Federico
    Mos, Fernando
    Petroni, Jorgelina
    Casanova, Matias
    Reniero, Liliana
    Roberti, Javier
    TRANSPLANT IMMUNOLOGY, 2015, 32 (01) : 35 - 39
  • [37] Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study.
    Divard, G.
    Debiais, C.
    Legendre, C.
    Aubert, O.
    Lefaucheur, C.
    Loupy, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 513 - 513
  • [38] MAINTENANCE IMMUNOSUPPRESSIVE THERAPY WITH BELATACEPT AFTER HEART AND KIDNEY TRANSPLANTATION
    Thaiss, F.
    Barten, M. J.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 34 - 34
  • [39] Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation
    Grellier, Jimmy
    Del Bello, Arnaud
    Milongo, David
    Guilbeau-Frugier, Celine
    Rostaing, Lionel
    Kamar, Nassim
    TRANSPLANT INTERNATIONAL, 2015, 28 (09) : 1109 - 1110
  • [40] De-Novo Belatacept Therapy is Associated with an Increased Risk of Invasive CMV Disease After Kidney Transplantation.
    Petrossian, G.
    Ortiz, J.
    Addonizio, K.
    Hsiao, A.
    Teixeira, L.
    Koizumi, N.
    James, R.
    Patel, S.
    Conti, D.
    Plews, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 512 - 512
12345